» Articles » PMID: 18367361

Hypoparathyroidism and Intracerebral Calcification in Patients with Beta-thalassemia Major

Overview
Journal Eur J Radiol
Specialty Radiology
Date 2008 Mar 28
PMID 18367361
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hypoparathyroidism is one of the most important endocrine complications of thalassemia major. This study was conducted to evaluate the prevalence of intracerebral calcifications in patients with thalassemia with and without hypoparathyroidism.

Methods: 47 beta-thalassemia patients with hypoparathyroidism underwent a brain CT scan to investigate the presence and extent of intracerebral calcification. 30 age- and sex-matched beta-thalassemic patients with normal parathyroid function who had undergone brain CT for headache, or some other minor neurologic problems were also enrolled in the study serving as controls. The amount of intracerebral calcification, hematologic parameters, and some clinical findings were compared between both groups.

Results: Intracerebral calcification was present in 54.2% of beta-thalassemia patients with hypoparathyroidism. The most frequent sites of calcification were basal ganglia, and frontoparietal areas of the brain. Thalami, internal capsule, cerebellum and posterior fossa were other less frequently calcified regions of the brain. In contrast, there was no evidence of intracerebral calcifications in the 30 thalassemic patients with normal parathyroid function. There was not a statistically significant difference between serum ferritin concentrations in thalassemia patient with hypoparathyroidism and those with normal parathyroid function (2781 vs. 2178, P>0.05).

Conclusion: Intracranial calcification is a common finding in thalassemia patients with hypoparathyroidism, it can be extensive and involves most regions of the brain.

Citing Articles

Very low serum IGF-1 levels are associated with vertebral fractures in adult males with beta-thalassemia major.

Costanzo G, Naselli A, Arpi M, Piticchio T, Le Moli R, Belfiore A J Endocrinol Invest. 2024; 47(7):1691-1700.

PMID: 38526837 DOI: 10.1007/s40618-023-02270-6.


Endocrinopathies in beta thalassemia: a narrative review.

Venou T, Barmpageorgopoulou F, Peppa M, Vlachaki E Hormones (Athens). 2023; 23(2):205-216.

PMID: 38103163 DOI: 10.1007/s42000-023-00515-w.


Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron?.

Evangelidis P, Venou T, Fani B, Vlachaki E, Gavriilaki E Int J Mol Sci. 2023; 24(22).

PMID: 38003451 PMC: 10671246. DOI: 10.3390/ijms242216263.


An ICET- A survey on Hypoparathyroidism in Patients with Thalassaemia Major and Intermedia: A preliminary report.

De Sanctis V, Soliman A, Canatan D, Elsedfy H, Karimi M, Daar S Acta Biomed. 2018; 88(4):435-444.

PMID: 29350657 PMC: 6166174. DOI: 10.23750/abm.v88i4.6837.


Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major in Iran: A meta-analysis study.

Azami M, Sharifi A, Norozi S, Mansouri A, Sayehmiri K Caspian J Intern Med. 2017; 8(1):1-15.

PMID: 28503277 PMC: 5412243.